International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
Fostering education, research and practice in TDM and CT

Anti-Infective Drugs Committee

Neely Michael 150x200

Chair

Michael Neely
Los Angeles, CA, USA

contactus273x169

Contact Us
Scientific Committees
Anti-Infective Drugs Committee

Marriott Debbie 150x200

Vice-Chair

Debbie Marriott
Sydney, Australia

Background & Purpose of the Committee

Over the past few years the field of TDM in infectious diseases has evolved. Based on this the scope of the Antifungal Drugs committee was expanded to Anti-Infective Drugs committee in 2011 (without antiretroviral drugs). During 2013, the HIV drugs committee proposed to have a joint Anti-Infective Drugs committee to preserve active members and broaden our interaction between colleagues. The proposal to join form a new larger Anti-Infective Drug committee (2013) was accepted with great enthusiasm. The previous experience of both committees will be beneficial, in particular the interplay with the multidisciplinary fields of Infectious Diseases.

Anti-Infective Drugs TDM is a challenging issue. The availability of LC (MS-MS) methods offers the potential to move from microbiological assays to physical-chemical procedures for the determination of these drugs in biological samples. It also provides multi-drug determination per run in a turnaround time that meets clinical relevance.

The purpose of the committee is to promote the clinical application of the TDM of anti-infective drug therapy and the development of laboratory assays for the determination of anti-infective drug concentrations in a variety of body fluids and tissues.

  • To promote the use of adequate analytical assays to quantify anti-infective drugs in biological matrices;
  • To develop and update guidelines for TDM based on current knowledge of target drug exposures and relevant biomarkers; and
  • To encourage professionals to apply TDM in the field of infectious diseases and to report their results to increase the level of evidence for TDM.

Committee Initiatives for 2016/2017

  • To publish a white paper on study design to evaluate TDM of anti-infective drugs
  • To publish TDM guidelines for ‘high priority’ anti-infective drugs
  • To have members participate in different (inter)national committees with a focus on TDM of anti-infective drugs

Committee Initiatives Completed in 2014/2015

  • This committee was established in 2013.
  • IATDMCT supported the “3rd Annual Individualized Therapeutic Approach Group”, Barcelona, Spain, May 8-9, 2014 with many talks on anti-infectives
  • Dr. Neely was a visiting scholar sponsored by IATDMCT to conduct workshops and presentations largely focused on vancomycin and voriconazole
    • “Population Modeling with Pmetrics”, Christian Medical College, Vellore, Tamil Nadu, India, July 21-24, 2014
    • “Parametric and nonparametric dose optimization. Which is the best approach?”, University of Antioquia, Medellín, Colombia, November 7, 2014
    • “Population Modeling with Pmetrics”, Feevale University, Novo Hamborgo, Brazil, November 10-11, 2014

Additional Committee Resources

Coming Soon!
This section will be updated during the 2016 second phase website redesign.